Table 2.
Main results
| Author | Outcome | HR | 95% CI | NOS score |
|---|---|---|---|---|
| Breast cancer | ||||
| Johansen 1995 | OS | 2.2 | 0.83–5.81 | 7 |
| Jensen 2003 | OS | 2.57 | 1.6–4.1 | 9 |
| PFS | 1.96 | 1.2–3.1 | ||
| Johansen 2003 | OS | 1.77 | 1.03–3.06 | 8 |
| Yamac 2008 | OS | 1.004 | 1.00–1.07 | 7 |
| Wang 2012 | OS | 1.04 | 1.02–1.06 | 7 |
| DFS | 1.02 | 1.00–1.03 | ||
| Gastrointestinal tumors | ||||
| Cintin 1999 | OS | 1.4 | 1.1–1.8 | 8 |
| Chang 2009 | OS | 0.99 | 0.76–1.28 | 7 |
| Zhu 2012 | OS | 1.809 | 1.259–2.601 | 8 |
| Zhu 2012 | OS | 2.188 | 1.237–3.870 | 8 |
| Schultz 2013 | OS | 0.69 | 0.36–1.33 | 7 |
| OS | 1.30 | 1.03–1.64 | ||
| Liu 2014 | PFS | 1.653 | 1.123–2.416 | 7 |
| Tarpgaard 2014 | OS | 1.17 | 1.05–1.30 | 7 |
| PFS | 1.00 | 0.91–1.09 | ||
| Jensen 2016 | OS | 1.53 | 1.1–2.13 | 6 |
| OS | 2.89 | 1.84–4.53 | ||
| Thongsom 2016 | OS | 1.642 | 0.780–3.455 | 7 |
| Gramkow 2017 | OS | 1.19 | 1.05–1.34 | 6 |
| Fuksiewicz 2018 | OS | 1.5 | 0.36–6.2 | 7 |
| DFS | 0.93 | 0.39–2.24 | ||
| Ovarian cancer | ||||
| Dehn 2003 | OS | 2.27 | 1.27–4.06 | 7 |
| Høgdall 2003 | OS | 3.95 | 1.52–10.273 | 7 |
| Høgdall 2009 | OS | 2.13 | 1.40–3.25 | 7 |
| Boisen 2016 | OS | 1.97 | 0.90–4.32 | 7 |
| PFS | 2.91 | 1.07–7.92 | ||
| Lung cancer | ||||
| Johansen 2004 | OS | 1.96 | 1.13–3.40 | 7 |
| Choi 2010 | OS | 3.6 | 1.25–10.39 | 7 |
| Thöm 2010 | OS | 1.48 | 1.04–2.10 | 8 |
| Xu 2014 | OS | 1.84 | 1.08–3.15 | 7 |
| PFS | 1.12 | 1.01–1.23 | ||
| Matsuo 2019 | PFS | 1.119 | 0.992–1.262 | 7 |
| Urologic neoplasms | ||||
| Brasso 2006 | OS | 1.3 | 1.0–1.7 | 8 |
| Johansen 2007 | OS | 1.0 | 0.7–1.3 | 7 |
| Tschirdewahn 2014 | OS | 1.837 | 1.039–3.375 | 8 |
| Vom Dorp 2016 | OS | 3.854 | 2.222–6.686 | 8 |
| Väänänen 2017 | OS | 3.19 | 1.38–7.36 | 7 |
| Darr 2018 | OS | 0.933 | 0.621–1.401 | 6 |
| Melanoma | ||||
| Schmidt 2006 | OS | 3.6 | 1.7–7.7 | 9 |
| Schmidt 2006 | OS | 1.9 | 1.2–2.8 | 9 |
| Krogh 2016 | OS | 1.28 | 1.05–1.57 | 8 |
| Erturk 2017 | OS | 1.568 | 0.580–3.051 | 7 |
| Squamous cell carcinoma of the head and neck | ||||
| Roslind 2008 | OS | 2.16 | 1.39–3.35 | 9 |
| Multiple tumors | ||||
| Johansen 2009 | OS | 1.8 | 1.3–2.5 | 9 |
| Cervical adenocarcinoma | ||||
| Mitsuhashi 2009 | DFS | 11 | 1.29–97 | 8 |
| Glioblastoma | ||||
| Iwamoto 2011 | OS | 1.2 | 1.0–1.4 | 8 |
| Bernardi 2012 | OS | 1.97 | 1.03–3.8 | 6 |
| Gállego 2014 | OS | 1.21 | 0.89–1.64 | 7 |
| PFS | 1.09 | 0.83–1.42 | ||
HR hazard ratio, CI confidence interval, NOS Newcastle–Ottawa scale, OS overall survival, PFS progression-free survival, DFS disease-free survival